𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Identification of a functional estrogen-responsive enhancer element in the promoter 2 of PRDM2 gene in breast cancer cell lines

✍ Scribed by Ciro Abbondanza; Caterina De Rosa; Andrea D'Arcangelo; Marianna Pacifico; Clorinda Spizuoco; Giulio Piluso; Erika Di Zazzo; Patrizia Gazzerro; Nicola Medici; Bruno Moncharmont; Giovanni Alfredo Puca

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
723 KB
Volume
227
Category
Article
ISSN
0021-9541

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The retinoblastoma protein‐interacting zinc‐finger (RIZ) gene, also known as PRDM2, encodes two protein products, RIZ1 and RIZ2, differing for the presence of a 202 aa domain, called PR domain, at the N‐terminus of the RIZ1 molecule. While the histone H3 K9 methyltransferase activity of RIZ1 is associated with the negative control of cell proliferation, no information is currently available on either expression regulation of the RIZ2 form or on its biological activity. RIZ proteins act as ER co‐activators and promote optimal estrogen response in female reproductive tissues. In estrogen‐responsive cells, 17‐β estradiol modulates RIZ gene expression producing a shift in the balanced expression of the two forms. Here, we demonstrate that an estrogen‐responsive element (ERE) within the RIZ promoter 2 is regulated in a ligand‐specific manner by ERα, through both the AF1 and AF2 domains. The pattern of ERα binding, histone H4 acetylation, and histone H3 cyclical methylation of lysine 9 was comparable to other estrogen‐regulated promoters. Association of topoisomerase IIβ with the RIZ promoter 2 confirmed the transcriptional activation induced by estrogen. We hypothesize that RIZ2, acting as a negative regulator of RIZ1 function, mediates the proliferative effect of estrogen through regulation of survival and differentiation gene expression. J. Cell. Physiol. 227: 964–975, 2012. © 2011 Wiley Periodicals, Inc.

📜 SIMILAR VOLUMES

Identification of a novel breast-cancer-
Identification of a novel breast-cancer-anti-estrogen-resistance (BCAR2) locus by cell-fusion-mediated gene transfer in human breast-cancer cells
✍ Lambert C.J. Dorssers; Jos Veldscholte 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 177 KB 👁 2 views

Development of anti-estrogen resistance limits the benefit of endocrine therapy of breast cancer. The mechanistic basis for resistance to the anti-estrogen tamoxifen may involve (epi)genetic alterations within tumor cells. We have initiated a random search for genes allowing estrogen-dependent ZR-75

Association of a functional polymorphism
Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer
✍ Helge Lind; Shanbeh Zienolddiny; Per Olav Ekstrøm; Vidar Skaug; Aage Haugen 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 73 KB 👁 2 views

## Abstract Lung cancer is the leading cause of cancer mortality in the world. Although exposure to carcinogens is considered to be the main cause, genetic variation may contribute to lung cancer risk. Murine double minute 2, MDM2, is a key regulator of p53 activity and recently a polymorphism in t

Identification and characterization of a
Identification and characterization of a negative regulatory element within the epidermal growth factor receptor gene first intron in hormone-dependent breast cancer cells
✍ Melissa A. Wilson; Susan A. Chrysogelos 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 198 KB

## Abstract The epidermal growth factor receptor (EGFR) exhibits an inverse correlation with estrogen receptor (ER) expression in the majority of breast cancers, predicting a poor response to endocrine therapy and poor survival rate. Inappropriate overexpression of EGFR in breast cancer is associat

Analysis of mutations and identification
Analysis of mutations and identification of several polymorphisms in the putative promoter region of the P34CDC2-related CDC2L1 gene located at 1P36 in melanoma cell lines and melanoma families
✍ Yongmei Feng; Jiaqi Shi; Alisa M. Goldstein; Margaret A. Tucker; Mark A. Nelson 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 257 KB

## Abstract Chromosome 1 abnormalities are the most commonly detected aberrations in many cancers including malignant melanoma. Partial deletions and an allelic loss of the chromosome 1p36 region observed in melanoma indicate the presence of putative tumor suppressor gene(s) in this region. A candi